about
Unique transcriptional profile of sustained ligand-activated preconditioning in pre- and post-ischemic myocardium.Dysfunctional survival-signaling and stress-intolerance in aged murine and human myocardium.Sarcolemmal cholesterol and caveolin-3 dependence of cardiac function, ischemic tolerance, and opioidergic cardioprotectionSustained ligand-activated preconditioning via δ-opioid receptorsOpioid receptors and cardioprotection - 'opioidergic conditioning' of the heartSarcolemmal dependence of cardiac protection and stress-resistance: roles in aged or diseased hearts.Delta Opioid Receptors and Cardioprotection.Chronic β1-adrenoceptor blockade impairs ischaemic tolerance and preconditioning in murine myocardiumCoupling of myocardial stress resistance and signalling to voluntary activity and inactivity.Bitter taste receptor agonists elicit G-protein-dependent negative inotropy in the murine heart.Differential immunological profiles herald magnetic resonance imaging-defined perioperative cerebral infarction.Inflammation and lung injury in an ovine model of fluid resuscitated endotoxemic shockPre-clinical study protocol: Blood transfusion in endotoxaemic shockNeuron-Specific Enolase and Matrix Metalloproteinase 9 Signal Perioperative Silent Brain Infarction During or After Transcatheter Aortic Valve ImplantationRegulation of the β-Adrenergic Receptor Signaling Pathway in Sustained Ligand-Activated PreconditioningComplex Effects of Putative DRP-1 Inhibitors on Stress Responses in Mouse Heart and Rat CardiomyoblastsHurdles to Cardioprotection in the Critically IllUntapped potential in Australian Hospitals for organ donation after circulatory death
P50
Q31132643-F19522EE-7D86-45D3-901B-E87B7603FA70Q33895695-25B86CFE-429E-46FA-99A6-F4DE8C0DC01DQ34201061-452604AA-E1AE-4F66-8465-74A3E4D6A83AQ34458657-7A1A8301-AC50-43ED-938C-78B7581FCF6BQ35286353-23878F43-6F1E-4058-945D-FC234A9E993FQ38903618-075A5D21-BFB2-4873-8856-E5930384115DQ39151222-C72B3192-3CEC-4C94-9CC6-8482D669D40BQ39635677-46A964A6-52B6-4776-BF88-70BD9A587C67Q39770064-9B8FCDAD-D61B-4E6A-AFE1-1391E843E0AEQ53097600-898615B3-74A5-4F2F-81F8-FF4B624912CAQ55455975-83CA2D47-37A1-4767-A40B-F2EF34A34831Q59329666-F01A9FAA-D0F3-4A5D-991F-DF82246B7714Q64274258-2850D8F6-D41A-4EBF-98B2-05A0B6797D0BQ90025350-AF16CF2E-F7C2-4A0C-A7CE-361E72AA2417Q91010458-52618A1D-8BDA-4246-B64F-3167355AC051Q91197539-5E183477-2D94-410E-BBEA-210990D680B4Q92454801-CBD824C8-1191-4EF8-AFC4-9A48632C1F9CQ95514717-06659CF6-6475-47B1-8006-9AF4F3CB174A
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Louise E See Hoe
@ast
Louise E See Hoe
@en
Louise E See Hoe
@es
Louise E See Hoe
@nl
type
label
Louise E See Hoe
@ast
Louise E See Hoe
@en
Louise E See Hoe
@es
Louise E See Hoe
@nl
prefLabel
Louise E See Hoe
@ast
Louise E See Hoe
@en
Louise E See Hoe
@es
Louise E See Hoe
@nl
P106
P31
P496
0000-0003-0553-205X